M&R Capital Management Inc. Has $1.05 Million Position in DENTSPLY SIRONA Inc. (XRAY)

M&R Capital Management Inc. lowered its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 8.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,503 shares of the medical instruments supplier’s stock after selling 1,600 shares during the quarter. M&R Capital Management Inc.’s holdings in DENTSPLY SIRONA were worth $1,046,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Commonwealth Bank of Australia grew its stake in DENTSPLY SIRONA by 19.0% during the second quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 260 shares during the last quarter. Acrospire Investment Management LLC bought a new stake in DENTSPLY SIRONA during the second quarter worth about $113,000. Dupont Capital Management Corp bought a new stake in shares of DENTSPLY SIRONA during the second quarter valued at approximately $116,000. Massey Quick Simon & CO. LLC bought a new stake in shares of DENTSPLY SIRONA during the third quarter valued at approximately $124,000. Finally, Korea Investment CORP grew its stake in shares of DENTSPLY SIRONA by 139.9% during the second quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock valued at $139,000 after purchasing an additional 1,251 shares during the last quarter. 96.58% of the stock is currently owned by institutional investors and hedge funds.

In related news, CFO Nicholas W. Alexos bought 50,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $65.85 per share, for a total transaction of $3,292,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. Company insiders own 1.99% of the company’s stock.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) opened at $65.50 on Thursday. DENTSPLY SIRONA Inc. has a 12-month low of $52.53 and a 12-month high of $68.98. The company has a market cap of $15,069.50, a PE ratio of 26.14, a PEG ratio of 2.60 and a beta of 1.31. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. DENTSPLY SIRONA’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.66 EPS. sell-side analysts expect that DENTSPLY SIRONA Inc. will post 2.66 earnings per share for the current year.

Several equities research analysts have weighed in on XRAY shares. Stifel Nicolaus reiterated a “buy” rating and issued a $66.00 target price (down from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Morgan Stanley raised their price objective on shares of DENTSPLY SIRONA from $66.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, August 10th. UBS reaffirmed a “neutral” rating and issued a $59.00 target price (down previously from $62.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. TheStreet downgraded shares of DENTSPLY SIRONA from a “b” rating to a “c+” rating in a research report on Wednesday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $68.00 target price (down previously from $74.00) on shares of DENTSPLY SIRONA in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. DENTSPLY SIRONA has a consensus rating of “Hold” and an average price target of $67.73.

TRADEMARK VIOLATION WARNING: “M&R Capital Management Inc. Has $1.05 Million Position in DENTSPLY SIRONA Inc. (XRAY)” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/07/mr-capital-management-inc-has-1-05-million-position-in-dentsply-sirona-inc-xray.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

What are top analysts saying about DENTSPLY SIRONA Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DENTSPLY SIRONA Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit